Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer

Completed · Phase 2

Conditions studied: Colorectal Cancer

In brief

RATIONALE: 5FU based neoadjuvant chemoradiation (nCRT) is the standard of care for Stage II/III rectal cancer. Pathologic complete response (pCR) and downstaging have been associated with improved outcomes. The addition of oxaliplatin (OXA) to neoadjuvant therapy may reduce distant disease recurrence. Adjuvant treatment with OXA for rectal cancer has been motivated by benefits demonstrated in stage III colon cancer. Objective: To determine the feasibility, toxicity, and efficacy of preoperative OXA/5FU and RT followed by total mesorectal excision (TME) and adjuvant PURPOSE: This phase II trial is studying the side effects and how well giving neo-adjuvant combination chemotherapy with radiation works in treating patients undergoing surgery for rectal cancer.

Key facts

Study ID

NCT00831181

Run by

Beth Israel Medical Center

People needed

27

Starts

2004-07-01

Expected to finish

2009-11-01

Last updated by the study team

2018-03-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven adenocarcinoma of the rectum with no distant metastases.
• T3-4N0M0, TanyN1-3M0 assessed by clinical exam, TRUS, MRI and CT
• The distal border of the tumor must be at or below the peritoneal reflection, defined as within 12 centimeters of the anal verge by protoscopic examination.
• No prior chemotherapy or pelvic irradiation.
• ECOG performance status 0-1
• Age 18 to 70 years
• ANC >= 1500/mm3 and platelets >= 100,000/mm3
• Serum creatinine <= 1.5 x ULN; bilirubin <= 1.5 x ULN; ALT<= 2.5 x ULN

You may not qualify if…

• Pregnant or lactating females; patients not practicing active contraception while sexually active.
• No other serious medical condition
• A psychiatric disorder that would prohibit the subject from participating fully.
• Peripheral neuropathy > grade 1
• History within the past 5 years of a cancer diagnosis except for non-melanomatous skin cancers or in situ cervix carcinoma.
• HIV positive patients

Where it is running

• Beth Israel Medical Center - Philipps Ambulatory Care Center — New York, New York, United States
• St. Luke's-Roosevelt Hospital Center - Roosevelt Division — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.